Sylvia Adams

31.1k total citations · 12 hit papers
181 papers, 14.8k citations indexed

About

Sylvia Adams is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Sylvia Adams has authored 181 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 79 papers in Pulmonary and Respiratory Medicine and 44 papers in Immunology. Recurrent topics in Sylvia Adams's work include Cancer Immunotherapy and Biomarkers (87 papers), Advanced Breast Cancer Therapies (40 papers) and Immunotherapy and Immune Responses (40 papers). Sylvia Adams is often cited by papers focused on Cancer Immunotherapy and Biomarkers (87 papers), Advanced Breast Cancer Therapies (40 papers) and Immunotherapy and Immune Responses (40 papers). Sylvia Adams collaborates with scholars based in United States, Australia and United Kingdom. Sylvia Adams's co-authors include Sherene Loi, Hiroji Iwata, Hope S. Rugo, Eric P. Winer, Luciana Molinero, Peter Schmid, Leisha A. Emens, Véronique Dièras, Carlos H. Barrios and Jane Yuet Ching Hui and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Sylvia Adams

169 papers receiving 14.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

2018 3.0k citations Peter Schmid, Sylvia Adams et al. profile →
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

2014 953 citations Sylvia Adams, Robert J. Gray et al. Journal of Clinical Oncology profile →
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

2019 846 citations Peter Schmid, Sylvia Adams et al. profile →
NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis

2017 587 citations Samantha Alvarez, Vladislav O. Sviderskiy et al. profile →
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial

2015 505 citations Sylvia Adams, James S. Babb et al. profile →
Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes

2018 477 citations Sylvia Adams et al. profile →
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

2016 424 citations Sylvia Adams et al. profile →
The Intestinal Microbiome and Estrogen Receptor–Positive Female Breast Cancer

2016 390 citations Maryann Kwa, Claudia S. Plottel et al. JNCI Journal of the National Cancer Institute profile →
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

2013 350 citations Jyoti D. Patel, Sylvia Adams et al. Journal of Clinical Oncology profile →
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

2021 293 citations Leisha A. Emens, Sylvia Adams et al. Annals of Oncology profile →
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

2021 205 citations Leisha A. Emens, Luciana Molinero et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by Sylvia Adams

Since Specialization

Citations

This map shows the geographic impact of Sylvia Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvia Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvia Adams more than expected).

Fields of papers citing papers by Sylvia Adams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvia Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvia Adams. The network helps show where Sylvia Adams may publish in the future.

Co-authorship network of co-authors of Sylvia Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvia Adams. A scholar is included among the top collaborators of Sylvia Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvia Adams. Sylvia Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Peritumoral macrophages recruit eosinophils to promote antitumor immune responses in breast cancer 2025 ·Proceedings of the National Academy of Sciences ·Joseph A. Saglimbeni, (unknown), Janet Ofelia Guevara Canales, Oriana A. Perez, (unknown), (unknown), Kamal M. Khanna, Igor Dolgalev, (unknown), Sylvia Adams, Boris Reizis	0
2	Evaluation of the gut microbiome and sex hormones in postmenopausal women with newly diagnosed hormone receptor-positive breast cancer versus healthy women: a prospective case-control study 2025 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), Yelena Novik, Adrian A. Franke, (unknown), Karina Martínez‐Flores, Martin J. Blaser, James L. Speyer, Ruth Oratz, Marleen Meyers, Komal Jhaveri, (unknown), Adriana Heguy, Jonas Schlüter, (unknown), Sylvia Adams	1
3	Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches 2024 ·Journal of Neuro-Oncology ·(unknown), (unknown), (unknown), Sylvia Adams, (unknown), Ying Meng, Zane Schnurman, Bernadine R. Donahue, Kenneth Bernstein, Cordelia Orillac, (unknown), Maryann Kwa, Marleen Meyers, Ruth Oratz, Yelena Novik, Joshua S. Silverman, David H. Harter, John G. Golfinos, Douglas Kondziolka	0
4	A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC. 2023 ·Journal of Clinical Oncology ·(unknown), Rohit Joshi, Joanne Chiu, Ann Chen, Hao Wang, Jared Odegard, (unknown), Sylvia Adams	1
5	Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment 2020 ·Breast Cancer Research and Treatment ·Jiehui Deng, Aatish Thennavan, (unknown), Ece Bagdatlioglu, (unknown), Adriana Heguy, Christian Marier, Peter Meyn, Yutong Zhang, Kristen Labbe, Christina Almonte, Michelle Krogsgaard, Charles M. Perou, Kwok‐Kin Wong, Sylvia Adams	14
6	LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer 2020 ·Annals of Oncology ·Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Hiroji Iwata, Sherene Loi, H. S. Rugo, Andreas Schneeweiß, Eric P. Winer, Shilpen Patel, Volkmar Henschel, A. Swat, Manika Kaul, Luciana Molinero, Jane Yuet Ching Hui, Peter Schmid	44
7	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis 2019 ·Clinical Cancer Research ·Melinda L. Telli, Charles C. Chu, Sunil Badve, Shaveta Vinayak, Daniel P. Silver, Steven J. Isakoff, Virginia Kaklamani, William J. Gradishar, Vered Stearns, Roisín M. Connolly, James M. Ford, Joshua J. Gruber, Sylvia Adams, Judy E. Garber, Nadine Tung, Chris Neff, Ryan Bernhisel, Kirsten M. Timms, Andrea L. Richardson	23
8	Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer 2018 ·Clinical Cancer Research ·Silvia C. Formenti, Percy Lee, Sylvia Adams, Judith D. Goldberg, Xiaochun Li, (unknown), Josephine A. Ratikan, Carol Felix, Lin Hwang, Kym F. Faull, James Sayre, Sara A. Hurvitz, John A. Glaspy, Begoña Comı́n-Anduix, Sandra Demaria, Dörthe Schaue, William H. McBride	205
9	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy 2018 ·Annals of Oncology ·(unknown), Roberto Salgado, Maria Vittoria Dieci, Andrea Vingiani, Giuseppe Curigliano, Rebekah Gould, Carlos A. Castañeda, Timothy M. D’Alfonso, Joselyn Sanchez, Esther Cheng, Eleni Andreopoulou, Miluska Castillo, Sylvia Adams, Sandra Demaria, W. Fraser Symmans, Stefan Michiels, Sherene Loi	119
10	Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. 2017 ·Journal of Clinical Oncology ·Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michelino De Laurentiis, Rita Nanda, Eric P. Winer, Hirofumi Mukai, Kenji Tamura, Anne Armstrong, Minetta C. Liu, Hiroji Iwata, Larisa Ryvo, Pauline Wimberger, Deborah Card, Yu Ding, Vassiliki Karantza, Peter Schmid	55
11	NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis 2017 ·DSpace@MIT (Massachusetts Institute of Technology) ·Samantha Alvarez, Vladislav O. Sviderskiy, Erdem M. Terzi, Thales Papagiannakopoulos, André L. Moreira, Sylvia Adams, Kıvanç Birsoy, David M. Sabatini, Richard Possemato	150
12	The Intestinal Microbiome and Estrogen Receptor–Positive Female Breast Cancer breakdown → 2016 ·JNCI Journal of the National Cancer Institute ·Maryann Kwa, Claudia S. Plottel, Martin J. Blaser, Sylvia Adams	390
13	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 breakdown → 2014 ·Journal of Clinical Oncology ·Sylvia Adams, Robert J. Gray, Sandra Demaria, Lori J. Goldstein, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Molin Wang, Vicky Jones, Thomas J. Saphner, Antonio C. Wolff, William C. Wood, Nancy E. Davidson, George W. Sledge, Joseph A. Sparano, Sunil Badve	953
14	Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer 2012 ·Clinical Cancer Research ·Sylvia Adams, Lina Kozhaya, Frank Martiniuk, Tze‐Chiang Meng, Luis Chiriboga, Leonard Liebes, Tsivia Hochman, (unknown), Deborah Axelrod, James L. Speyer, Yelena Novik, Amy Tiersten, Judith D. Goldberg, Silvia C. Formenti, Nina Bhardwaj, Derya Unutmaz, Sandra Demaria	184
15	Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer 2012 ·Clinical Cancer Research ·Md. Zahidunnabi Dewan, Claire Vanpouille‐Box, Noriko Kawashima, Sarah R. DiNapoli, James S. Babb, Silvia C. Formenti, Sylvia Adams, Sandra Demaria	125
16	Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology 2011 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, (unknown), Sylvia Adams, Carol Aghajanian, Susan M. Chang, ZoAnn E. Dreyer, Pasi A. Jänne, Andrew H. Ko, (unknown), Olatoyosi Odenike, Jyoti D. Patel, Bruce J. Roth, Wolfram E. Samlowski, Andrew D. Seidman, William D. Tap, Jennifer S. Temel, Jamie H. Von Roenn, Mark G. Kris	68
17	Lung Bullae With Air-Fluid Levels: What Is the Appropriate Therapeutic Approach? 2011 ·Respiratory Care ·Andrés F. Henao‐Martínez, Juan F. Fernandez, Sylvia Adams, Carlos S. Restrepo	8
18	Type 2 Bias of T Cells Expanded from the Blood of Melanoma Patients Switched to Type 1 by IL-12p70 mRNA–Transfected Dendritic Cells 2008 ·Cancer Research ·Kira Minkis, Daniel G. Kavanagh, Galit Alter, Dusan Bogunovic, David O’Neill, Sylvia Adams, Anna C. Pavlick, Bruce D. Walker, Mark A. Brockman, Rajesh T. Gandhi, Nina Bhardwaj	46
19	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. 2007 ·PubMed Central ·Elsa F. Velázquez, Achim A. Jungbluth, Molly Yancovitz, Sacha Gnjatic, Sylvia Adams, David O’Neill, (unknown), (unknown), Paul J. Christos, Madhu Mazumdar, Anna C. Pavlick, David Polsky, Richard L. Shapiro, Russell S. Berman, (unknown), Klaus J. Busam, Iman Osman, Nina Bhardwaj	97
20	Managing COPD: How to deal with the most common problems 2005 ·Sylvia Adams	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact